{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:32:43Z","timestamp":1770719563058,"version":"3.49.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,1,17]],"date-time":"2009-01-17T00:00:00Z","timestamp":1232150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s12016-009-8118-1","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T01:35:53Z","timestamp":1232069753000},"page":"58-66","source":"Crossref","is-referenced-by-count":43,"title":["Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors"],"prefix":"10.1007","volume":"37","author":[{"given":"Kanjaksha","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrimati","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,17]]},"reference":[{"key":"8118_CR1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","volume":"2","author":"SC Darby","year":"2004","unstructured":"Darby SC, Keeling DM, Spooner RJ et al (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2:1047\u20131054","journal-title":"J Thromb Haemost"},{"key":"8118_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2516.1999.00321.x","volume":"5","author":"H Chang","year":"1999","unstructured":"Chang H, Sher GD, Blanchette VS, Teitel JM (1999) The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 5:247\u2013252","journal-title":"Haemophilia"},{"key":"8118_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0268-960X(98)90021-2","volume":"12","author":"CV Prowse","year":"1998","unstructured":"Prowse CV, MacGregor IR (1998) Neoantigens and antibodies to factor VIII. Blood Rev 12:99\u2013105","journal-title":"Blood Rev"},{"key":"8118_CR4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1365-2516.2002.00687.x","volume":"8","author":"K Ghosh","year":"2002","unstructured":"Ghosh K, Jijina F, Shetty S, Madkaikar M, Mohanty D (2002) First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia 8:776\u2013780","journal-title":"Haemophilia"},{"key":"8118_CR5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1160\/TH07-08-0497","volume":"99","author":"G Lavigne-Lissalde","year":"2008","unstructured":"Lavigne-Lissalde G, Tarrade C, Lapalud P et al (2008) Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 99:1090\u20131096","journal-title":"Thromb Haemost"},{"key":"8118_CR6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jim.2005.10.016","volume":"308","author":"EM Kopecky","year":"2006","unstructured":"Kopecky EM, Greinstetter S, Pabinger I, Buchacher A, Romisch J, Jungbauer A (2006) Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. J Immunol Methods 308:90\u2013100","journal-title":"J Immunol Methods"},{"key":"8118_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000067272","volume":"109","author":"S Shetty","year":"2003","unstructured":"Shetty S, Ghosh K, Mohanty D (2003) An ELISA assay for the detection of factor VIII antibodies - comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol 109:18\u201322","journal-title":"Acta Haematol"},{"key":"8118_CR8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/s-0038-1648507","volume":"67","author":"Y Sultan","year":"1992","unstructured":"Sultan Y (1992) Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 67:600\u2013602","journal-title":"Thromb Haemost"},{"key":"8118_CR9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","volume":"339","author":"S Ehrenforth","year":"1992","unstructured":"Ehrenforth S, Kreuz W, Scharrer I et al (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594\u2013598","journal-title":"Lancet"},{"key":"8118_CR10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ng1193-236","volume":"5","author":"D Lakich","year":"1993","unstructured":"Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J (1993) Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 5:236\u2013241","journal-title":"Nat Genet"},{"key":"8118_CR11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.V99.1.168","volume":"99","author":"RD Bagnall","year":"2002","unstructured":"Bagnall RD, Waseem N, Green PM, Giannelli F (2002) Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 99:168\u2013174","journal-title":"Blood"},{"key":"8118_CR12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1538-7836.2003.00088.x","volume":"1","author":"M Jacquemin","year":"2003","unstructured":"Jacquemin M, De Maeyer M, D\u2019Oiron R, Lavend\u2019Homme R, Peerlinck K, Saint-Remy JM (2003) Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost 1:456\u2013463","journal-title":"J Thromb Haemost"},{"issue":"Suppl 6","key":"8118_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","volume":"12","author":"J Oldenburg","year":"2006","unstructured":"Oldenburg J, Pavlova A (2006) Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 12(Suppl 6):15\u201322","journal-title":"Haemophilia"},{"key":"8118_CR14","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1182\/blood-2006-06-026104","volume":"109","author":"KR Viel","year":"2007","unstructured":"Viel KR, Machiah DK, Warren DM et al (2007) A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 109:3713\u20133724","journal-title":"Blood"},{"key":"8118_CR15","first-page":"924","volume":"90","author":"J Astermark","year":"2005","unstructured":"Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E (2005) The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 90:924\u2013931","journal-title":"Haematologica"},{"key":"8118_CR16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood.V96.3.979","volume":"96","author":"ML Liu","year":"2000","unstructured":"Liu ML, Shen BW, Nakaya S et al (2000) Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 96:979\u2013987","journal-title":"Blood"},{"key":"8118_CR17","doi-asserted-by":"crossref","unstructured":"Boekhorst J, Lari GR, D\u2019Oiron R et al (2008) Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia 14:729\u2013735","DOI":"10.1111\/j.1365-2516.2008.01694.x"},{"key":"8118_CR18","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1538-7836.2007.02591.x","volume":"5","author":"Y Repesse","year":"2007","unstructured":"Repesse Y, Slaoui M, Ferrandiz D et al (2007) Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. J Thromb Haemost 5:1469\u20131476","journal-title":"J Thromb Haemost"},{"key":"8118_CR19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2516.2006.01297.x","volume":"12","author":"M Franchini","year":"2006","unstructured":"Franchini M, Girelli D, Olivieri O et al (2006) Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild\/moderate haemophilia A. Haemophilia 12:448\u2013451","journal-title":"Haemophilia"},{"key":"8118_CR20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2516.1998.440558.x","volume":"4","author":"CR Hay","year":"1998","unstructured":"Hay CR (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 4:558\u2013563","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"8118_CR21","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/00001721-200306001-00005","volume":"14","author":"A Goodeve","year":"2003","unstructured":"Goodeve A (2003) The incidence of inhibitor development according to specific mutations\u2013and treatment? Blood Coagul Fibrinolysis 14(Suppl 1):S17\u201321","journal-title":"Blood Coagul Fibrinolysis"},{"key":"8118_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2516.2001.00510.x","volume":"7","author":"J Astermark","year":"2001","unstructured":"Astermark J, Berntorp E, White GC, Kroner BL (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7:267\u2013272","journal-title":"Haemophilia"},{"key":"8118_CR23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1365-2141.1999.01268.x","volume":"104","author":"TT Yee","year":"1999","unstructured":"Yee TT, Pasi KJ, Lilley PA, Lee CA (1999) Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34\u00a0years, 1964-97. Br J Haematol 104:909\u2013914","journal-title":"Br J Haematol"},{"issue":"Suppl 6","key":"8118_CR24","first-page":"23","volume":"12","author":"CR Hay","year":"2006","unstructured":"Hay CR (2006) The epidemiology of factor VIII inhibitors. Haemophilia 12(Suppl 6):23\u201328; discussion 28-9","journal-title":"Haemophilia"},{"key":"8118_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","volume":"4","author":"LM Aledort","year":"1998","unstructured":"Aledort LM, Dimichele DM (1998) Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 4:68","journal-title":"Haemophilia"},{"key":"8118_CR26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0609.1973.tb00114.x","volume":"11","author":"BN Bouma","year":"1973","unstructured":"Bouma BN, van Mourik JA, Wiegerinck Y, Sixma JJ, Mochtar IA (1973) Immunological characterization of anti-haemophilic factor A related antigen in haemophilia A. Scand J Haematol 11:184\u2013187","journal-title":"Scand J Haematol"},{"key":"8118_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0038-1650129","volume":"45","author":"ML Kavanagh","year":"1981","unstructured":"Kavanagh ML, Wood CN, Davidson JF (1981) The immunological characterization of human antibodies to factor VIII isolated by immuno-affinity chromatography. Thromb Haemost 45:60\u201364","journal-title":"Thromb Haemost"},{"key":"8118_CR28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2141.1985.tb04072.x","volume":"61","author":"EH Moffat","year":"1985","unstructured":"Moffat EH, Bloom AL, Jones J, Matthews N, Newcombe RG (1985) A study of cell mediated and humoral immunity in haemophilia and related disorders. Br J Haematol 61:157\u2013167","journal-title":"Br J Haematol"},{"key":"8118_CR29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0037-1615873","volume":"82","author":"MT Reding","year":"1999","unstructured":"Reding MT, Wu H, Krampf M et al (1999) CD4 + T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 82:509\u2013515","journal-title":"Thromb Haemost"},{"key":"8118_CR30","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2005-09-3918","volume":"107","author":"J Astermark","year":"2006","unstructured":"Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK (2006) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 107:3167\u20133172","journal-title":"Blood"},{"key":"8118_CR31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/hmg\/1.5.353","volume":"1","author":"AG Wilson","year":"1992","unstructured":"Wilson AG, di Giovine FS, Blakemore AI, Duff GW (1992) Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1:353","journal-title":"Hum Mol Genet"},{"key":"8118_CR32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1365-3083.1996.d01-65.x","volume":"43","author":"G Bouma","year":"1996","unstructured":"Bouma G, Crusius JB, Oudkerk Pool M et al (1996) Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43:456\u2013463","journal-title":"Scand J Immunol"},{"key":"8118_CR33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1084\/jem.177.2.557","volume":"177","author":"AG Wilson","year":"1993","unstructured":"Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW (1993) An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557\u2013560","journal-title":"J Exp Med"},{"key":"8118_CR34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/s-0038-1647359","volume":"64","author":"LE Lippert","year":"1990","unstructured":"Lippert LE, Fisher LM, Schook LB (1990) Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost 64:564\u2013568","journal-title":"Thromb Haemost"},{"key":"8118_CR35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1655945","volume":"77","author":"J Oldenburg","year":"1997","unstructured":"Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E (1997) HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 77:238\u2013242","journal-title":"Thromb Haemost"},{"key":"8118_CR36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","volume":"77","author":"CR Hay","year":"1997","unstructured":"Hay CR, Ollier W, Pepper L et al (1997) HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 77:234\u2013237","journal-title":"Thromb Haemost"},{"key":"8118_CR37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","volume":"107","author":"J Goudemand","year":"2006","unstructured":"Goudemand J, Rothschild C, Demiguel V et al (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107:46\u201351","journal-title":"Blood"},{"issue":"Suppl 6","key":"8118_CR38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2516.2006.01373.x","volume":"12","author":"CE Ettingshausen","year":"2006","unstructured":"Ettingshausen CE, Kreuz W (2006) Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 12(Suppl 6):102\u2013106","journal-title":"Haemophilia"},{"key":"8118_CR39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ajh.20863","volume":"82","author":"G Tagariello","year":"2007","unstructured":"Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R (2007) In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 82:460\u2013462","journal-title":"Am J Hematol"},{"key":"8118_CR40","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","volume":"106","author":"C Hausl","year":"2005","unstructured":"Hausl C, Ahmad RU, Sasgary M et al (2005) High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 106:3415\u20133422","journal-title":"Blood"},{"key":"8118_CR41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.2005.05605.x","volume":"130","author":"E Santagostino","year":"2005","unstructured":"Santagostino E, Mancuso ME, Rocino A et al (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 130:422\u2013427","journal-title":"Br J Haematol"},{"key":"8118_CR42","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","volume":"109","author":"SC Gouw","year":"2007","unstructured":"Gouw SC, van der Bom JG, van den Berg HM (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109:4648\u20134654","journal-title":"Blood"},{"key":"8118_CR43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2516.2001.00505.x","volume":"7","author":"K Ghosh","year":"2001","unstructured":"Ghosh K, Shetty S, Kulkarni B et al (2001) Development of inhibitors in patients with haemophilia from India. Haemophilia 7:273\u2013278","journal-title":"Haemophilia"},{"key":"8118_CR44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00001721-199904000-00001","volume":"10","author":"E Zanon","year":"1999","unstructured":"Zanon E, Zerbinati P, Girolami B, Bertomoro A, Girolami A (1999) Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates. Blood Coagul Fibrinolysis 10:117\u2013120","journal-title":"Blood Coagul Fibrinolysis"},{"key":"8118_CR45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2003.04731.x","volume":"124","author":"P Collins","year":"2004","unstructured":"Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R (2004) A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 124:86\u201390","journal-title":"Br J Haematol"},{"key":"8118_CR46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0950-3536(96)80067-9","volume":"9","author":"AJ Cohen","year":"1996","unstructured":"Cohen AJ, Kessler CM (1996) Acquired inhibitors. Baillieres Clin Haematol 9:331\u2013354","journal-title":"Baillieres Clin Haematol"},{"key":"8118_CR47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","volume":"121","author":"J Delgado","year":"2003","unstructured":"Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 121:21\u201335","journal-title":"Br J Haematol"},{"issue":"3","key":"8118_CR48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","volume":"45","author":"D Green","year":"1981","unstructured":"Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemastos 45(3):200\u2013203","journal-title":"Thromb Haemastos"},{"key":"8118_CR49","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.V81.6.1513.1513","volume":"81","author":"AE Morrison","year":"1993","unstructured":"Morrison AE, Ludlam CA, Kessler C (1993) Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 81:1513\u20131520","journal-title":"Blood"},{"key":"8118_CR50","doi-asserted-by":"crossref","first-page":"730","DOI":"10.5858\/2000-124-0730-AHIPWH","volume":"124","author":"S Sallah","year":"2000","unstructured":"Sallah S, Nguyen NP, Abdallah JM, Hanrahan LR (2000) Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 124:730\u2013734","journal-title":"Arch Pathol Lab Med"},{"key":"8118_CR51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/1097-0142(20010315)91:6<1067::AID-CNCR1101>3.0.CO;2-4","volume":"91","author":"S Sallah","year":"2001","unstructured":"Sallah S, Wan JY (2001) Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 91:1067\u20131074","journal-title":"Cancer"},{"key":"8118_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1651666","volume":"73","author":"I Hauser","year":"1995","unstructured":"Hauser I, Schneider B, Lechner K (1995) Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 73:1\u20135","journal-title":"Thromb Haemost"},{"key":"8118_CR53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2516.2007.01618.x","volume":"14","author":"A Pavlova","year":"2008","unstructured":"Pavlova A, Diaz-Lacava A, Zeitler H et al (2008) Increased frequency of the CTLA-4 49 A\/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 14:355\u2013360","journal-title":"Haemophilia"},{"key":"8118_CR54","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ajh.20702","volume":"81","author":"M Franchini","year":"2006","unstructured":"Franchini M (2006) Postpartum acquired factor VIII inhibitors. Am J Hematol 81:768\u2013773","journal-title":"Am J Hematol"},{"key":"8118_CR55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00006254-200012000-00003","volume":"55","author":"SA Shobeiri","year":"2000","unstructured":"Shobeiri SA, West EC, Kahn MJ, Nolan TE (2000) Postpartum acquired hemophilia (factor VIII inhibitors): a case report and review of the literature. Obstet Gynecol Surv 55:729\u2013737","journal-title":"Obstet Gynecol Surv"},{"key":"8118_CR56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.1997.tb00733.x","volume":"59","author":"JJ Michiels","year":"1997","unstructured":"Michiels JJ, Hamulyak K, Nieuwenhuis HK, Novakova I, van Vliet HH (1997) Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VIII inhibitor. Eur J Haematol 59:105\u2013109","journal-title":"Eur J Haematol"},{"key":"8118_CR57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1096-8652(200010)65:2<154::AID-AJH11>3.0.CO;2-A","volume":"65","author":"DA Triplett","year":"2000","unstructured":"Triplett DA, Asherson RA (2000) Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 65:154\u2013159","journal-title":"Am J Hematol"},{"key":"8118_CR58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/jaut.2000.0419","volume":"15","author":"EN Harris","year":"2000","unstructured":"Harris EN, Pierangeli SS (2000) \u2018Equivocal\u2019 antiphospholipid syndrome. J Autoimmun 15:81\u201385","journal-title":"J Autoimmun"},{"key":"8118_CR59","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/art.1780310926","volume":"31","author":"P Small","year":"1988","unstructured":"Small P (1988) Severe hemorrhage in a patient with circulating anticoagulant, acquired hypoprothrombinemia, and systemic lupus erythematosus. Arthritis Rheum 31:1210\u20131211","journal-title":"Arthritis Rheum"},{"key":"8118_CR60","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-0038-1656029","volume":"77","author":"AN Blanco","year":"1997","unstructured":"Blanco AN, Cardozo MA, Candela M, Santarelli MT, Perez Bianco R, Lazzari MA (1997) Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost 77:656\u2013659","journal-title":"Thromb Haemost"},{"key":"8118_CR61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ajh.2830420221","volume":"42","author":"R Saxena","year":"1993","unstructured":"Saxena R, Dhot PS, Saraya AK, Singh H, Malhotra OP (1993) Simultaneous occurrence of factor VIIIC inhibitor and lupus anticoagulant. Am J Hematol 42:232\u2013233","journal-title":"Am J Hematol"},{"key":"8118_CR62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1096-8652(199603)51:3<250::AID-AJH2830510302>3.0.CO;2-L","volume":"51","author":"C Biron","year":"1996","unstructured":"Biron C, Durand L, Lemkecher T et al (1996) Simultaneous occurrence of lupus anticoagulant, factor VIII inhibitor and localized pemphigoid. Am J Hematol 51:250\u2013251","journal-title":"Am J Hematol"},{"key":"8118_CR63","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1055\/s-0037-1614875","volume":"82","author":"R Nuss","year":"1999","unstructured":"Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M (1999) Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group. Thromb Haemost 82:1559\u20131560","journal-title":"Thromb Haemost"},{"key":"8118_CR64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/rheumatology\/32.6.515","volume":"32","author":"HS Ballard","year":"1993","unstructured":"Ballard HS, Nyamuswa G (1993) Life-threatening haemorrhage in a patient with rheumatoid arthritis and a lupus anticoagulant coexisting with acquired autoantibodies against factor VIII. Br J Rheumatol 32:515\u2013517","journal-title":"Br J Rheumatol"},{"key":"8118_CR65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/107602960200800213","volume":"8","author":"E Lindhoff-Last","year":"2002","unstructured":"Lindhoff-Last E, Humpich M, Schmitt J, Rodiger S, Seifried E, Bauersachs R (2002) MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 8:163\u2013167","journal-title":"Clin Appl Thromb Hemost"},{"key":"8118_CR66","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1196\/annals.1423.017","volume":"1110","author":"G Candore","year":"2007","unstructured":"Candore G, Campagna AM, Cuppari I, Di Carlo D, Mineo C, Caruso C (2007) Genetic control of immune response in carriers of the 8.1 ancestral haplotype: correlation with levels of IgG subclasses: its relevance in the pathogenesis of autoimmune diseases. Ann NY Acad Sci 1110:151\u2013158","journal-title":"Ann NY Acad Sci"},{"key":"8118_CR67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1749-6632.2002.tb02999.x","volume":"958","author":"NK Mehra","year":"2002","unstructured":"Mehra NK, Kaur G, Kanga U, Tandon N (2002) Immunogenetics of autoimmune diseases in Asian Indians. Ann NY Acad Sci 958:333\u2013336","journal-title":"Ann NY Acad Sci"},{"key":"8118_CR68","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1182\/blood-2003-08-2803","volume":"102","author":"M Madkaikar","year":"2003","unstructured":"Madkaikar M, Ghosh K (2003) Treating patients of myelodysplastic syndrome with antithymocytic globulin\u2014should we be more selective? Blood 102:3851\u20133852; author reply 3852","journal-title":"Blood"},{"key":"8118_CR69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-065X.1998.tb01208.x","volume":"164","author":"CL Vanderlugt","year":"1998","unstructured":"Vanderlugt CL, Begolka WS, Neville KL et al (1998) The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 164:63\u201372","journal-title":"Immunol Rev"},{"key":"8118_CR70","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-9629(15)40651-2","volume":"318","author":"J Alumkal","year":"1999","unstructured":"Alumkal J, Rice L, Vempathy H, McCarthy JJ, Riggs SA (1999) Surgery-associated factor VIII inhibitors in patients without hemophilia. Am J Med Sci 318:350\u2013352","journal-title":"Am J Med Sci"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-009-8118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-009-8118-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-009-8118-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T02:36:57Z","timestamp":1632969417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-009-8118-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,17]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["8118"],"URL":"https:\/\/doi.org\/10.1007\/s12016-009-8118-1","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,17]]}}}